HB3084, titled the Oral Health and Cancer Rights Act, requires most health benefit plans regulated under West Virginia law to cover certain oral health medical procedures that are medically necessary because of cancer treatment. The bill applies to policies, plans, and contracts issued or renewed on or after January 1, 2026, and reaches a broad set of coverage types, including PEIA, Medicaid-related provisions, accident and sickness insurance, group insurance, hospital and medical service corporations, health care corporations, and HMOs.
The required coverage is tied to cancer treatments such as surgery, chemotherapy, biotherapy, pharmacology, immunotherapy, and radiation. It specifically includes evaluations, examinations, patient education, lab assessments, medications, treatments, restoration, rehabilitation, medical devices, and prostheses needed to support cancer treatment or restore function related to eating, breathing, voice, speech, and swallowing. In practical terms, the bill expands insurance coverage for oral and dental-related care that becomes necessary as a side effect of cancer treatment or as part of recovery from a cancer diagnosis.
The bill would add seven new sections across the West Virginia Code to mandate a new insurance coverage requirement for oral health procedures related to cancer treatment. It would affect state-regulated health plans and insurers by requiring them to cover these services for policies renewed or issued on or after January 1, 2026, likely increasing covered benefits and potentially affecting premium and claims costs. The measure also creates a uniform standard across multiple insurance chapters, reducing variation in coverage for cancer-related oral health care.
The available voting record suggests strong support for the bill: it passed the House 91-0. No committee transcript excerpts were provided, but the unanimous vote indicates broad bipartisan agreement and little visible opposition in the chamber. The bill’s subject matter—expanding medically necessary coverage for cancer patients—appears to have been viewed favorably as a patient-protection measure.
No specific points of contention are documented in the provided materials. Potential areas of debate in a bill like this could include cost to insurers, premium impacts, and the scope of procedures deemed medically necessary, but none of those concerns are reflected in the available transcripts or vote history. The bill’s broad coverage language and application across multiple insurance categories suggest the main policy question is implementation rather than whether coverage should be provided at all.